The story of laboratory-grown diamonds over the past decade is, depending on your position in the market, either a triumph of materials science democratizing luxury or a cautionary tale about what happens when supply constraints are removed from a product whose perceived value depended on them. For serious collectors and investors, it is something more specific: a case study in how rapidly a market can reprice when the scarcity narrative collapses.
Understanding where laboratory diamonds stand in 2026 — technically, commercially, and as potential investment assets — requires separating the manufacturing story from the marketing story, because they have diverged sharply.
Two Methods, One Product Category
Laboratory diamonds are grown through one of two primary processes, and the distinction between them matters both for quality assessment and for detection.
High Pressure High Temperature (HPHT) diamonds are produced by replicating the geological conditions under which natural diamonds form: intense pressure (around 5-6 GPa) and high temperature (1,200-1,600°C) are applied to a carbon source in the presence of a metallic catalyst and a diamond seed crystal. The result is a diamond that grows over weeks to months, depending on the target size.
HPHT diamonds were the first commercially viable laboratory method and have been in industrial use since the 1950s, with gem-quality production scaling through the 1990s and 2000s. The telltale characteristics of HPHT growth — including metallic inclusions from the catalyst, a specific pattern of strain visible under polarized light, and a distinctive fluorescence pattern — have been well-characterized by gemological laboratories and are reliably detectable.
Chemical Vapor Deposition (CVD) diamonds grow through a completely different mechanism: a hydrocarbon gas (typically methane) is introduced into a chamber with a diamond seed crystal, and plasma energy causes carbon atoms to deposit layer by layer onto the seed. CVD diamonds grow at lower temperatures and pressures than HPHT and can be produced in larger reactors with more seeds simultaneously.
CVD technology has scaled dramatically over the past decade. Production costs, which were above $400 per carat of polished output in 2015, had fallen below $50 per carat of polished production by 2023 and continue to decline. This cost reduction is the driver of the price collapse that has restructured the market.
Quality Differences: What Matters in 2026
Early CVD diamonds carried specific quality signatures that limited their acceptance in the fine jewelry market. Type IIa chemistry (CVD diamonds are nitrogen-free by nature), combined with the layered growth mechanism, produced stones with brownish residual color that required post-growth HPHT treatment to achieve colorless grades. This post-growth treatment added cost and a detection complication — CVD diamonds that have been post-treated to improve color show a characteristic combination of CVD growth structure and HPHT treatment signature.
By 2024-2026, the technology has matured sufficiently that top CVD producers are consistently achieving D-E-F color without post-growth treatment, with VVS-to-IF clarity in sizes up to five carats. The quality ceiling for CVD production has risen to the point where distinguishing a well-grown CVD diamond from a fine natural diamond requires sophisticated laboratory equipment; visual inspection, even by experienced graders, is not reliable.
HPHT diamonds continue to be produced, and the color achievable through HPHT growth — particularly fancy vivid yellows and some blues — benefits from the chemistry of the growth environment. For fancy colored laboratory diamonds, HPHT remains competitive. For colorless grades, CVD has become the dominant technology.
The practical quality difference for buyers in 2026 is minimal at the top end of laboratory production. Both methods, executed by skilled producers, can deliver stones that satisfy every optical and physical specification a buyer might set. The meaningful differences are in detectability, not in appearance or physical properties.
The Price Collapse: From $800 to Under $200 Per Carat
The trajectory of laboratory diamond prices from 2019 to 2026 is among the most dramatic price collapses in any consumer product category. In 2019, a one-carat round brilliant CVD diamond of D-VS1 quality sold at retail for approximately $800 to $1,200, depending on the vendor. By mid-2023, the same specifications were available for $300 to $400. By 2025, retail prices for laboratory diamonds at this specification had fallen below $200 per carat at competitive online vendors, with wholesale costs to retailers at $30 to $60 per carat.
The mechanism of this collapse is straightforward: capital investment in CVD production expanded rapidly following the 2019-2021 period when laboratory diamond retail prices were still high enough to generate attractive margins. Indian manufacturers — particularly in Surat, the world’s largest diamond cutting center — invested heavily in CVD reactors, adding production capacity at a rate that outpaced demand growth. By 2023, the market faced a structural oversupply that compressed margins throughout the supply chain.
There is no technical or geological ceiling on CVD diamond production. Unlike natural diamonds, where larger rough is genuinely rare, CVD reactors can be scaled. The price collapse is not a temporary dislocation; it is the market finding the new structural price level for laboratory-grown carbon.
De Beers Lightbox: Strategic Positioning in a Disrupted Market
De Beers, the world’s largest natural diamond producer and historically the architect of the “diamonds are forever” narrative, entered the laboratory diamond market in 2018 with the Lightbox brand. The strategic logic was explicit and publicly acknowledged: by establishing a laboratory diamond sub-brand with deliberately constrained pricing — initially $800 per carat for all sizes and colors — De Beers sought to define laboratory diamonds as fashion accessories rather than investment assets.
The Lightbox strategy communicated a clear message: these are beautiful, fun, affordable fashion items that belong in a completely different category from natural diamonds. By pricing them low and deliberately, De Beers was attempting to prevent the laboratory diamond narrative from migrating upmarket and threatening the natural diamond investment argument.
The strategy has had mixed results. Lightbox established a retail presence and attracted customers seeking non-precious jewelry alternatives. But the broader laboratory diamond market ignored De Beers’ preferred positioning; competing producers and retailers continued marketing laboratory diamonds as equivalent-quality alternatives to natural stones, at what they described as more ethical and accessible price points.
By 2025, the price collapse had overtaken even Lightbox’s original retail pricing, with competing laboratory diamonds available well below Lightbox prices. De Beers has recalibrated Lightbox’s positioning and pricing multiple times, reflecting the difficulty of controlling market narrative when production economics are driving the actual prices.
Retailer Response: Diverging Strategies
Traditional jewelry retailers have responded to laboratory diamonds with strategies ranging from full embrace to quiet avoidance, reflecting their assessment of where the category is going.
Signet Jewelers — the world’s largest specialty jewelry retailer, operating Kay Jewelers, Zales, and Jared — has leaned aggressively into laboratory diamonds, training staff to present them as the preferred choice for budget-conscious engagement ring buyers. The margin structure on laboratory diamonds allows retailers to capture significant gross profit dollars even at lower retail price points, as long as the wholesale cost continues to decline faster than the retail price.
Independent and fine jewelry retailers have been more cautious. Those whose positioning relies on quality, craftsmanship, and the investment narrative of natural stones have generally avoided laboratory diamonds or treat them as a separate, clearly marked offering. The concern is that conflating laboratory and natural diamonds at the retail level undermines the premium narrative for both.
The engagement ring market — traditionally the largest consumer category for diamonds — has seen some substitution toward laboratory stones but less than early advocates predicted. Surveys consistently show that a majority of engagement ring buyers still prefer natural diamonds when given clear disclosure of the difference, though the preference margin has narrowed.
The Investment Reality: Unambiguous
On the question of laboratory diamond investment value, the answer that the market has delivered is unambiguous: there is none.
The investment case for natural diamonds rests on geological scarcity — the finite supply of rough from a depleted number of economically viable mines, the long lead time for new supply, and the consequent long-term pressure on prices for fine material. None of these factors apply to laboratory diamonds. Production can be expanded as rapidly as capital can build reactors. The price trajectory since 2019 demonstrates this clearly.
A laboratory diamond purchased in 2019 for $1,000 is worth less than $200 in 2026. There is no reason, structural or technical, to expect the price decline to reverse. As production technology continues to improve and scale, the floor for laboratory diamond prices is likely the marginal cost of production — which is declining toward tens of dollars per carat and will continue to decline.
Retailers who marketed laboratory diamonds in 2020-2022 using language about “value” and “smart choice” did their customers a disservice. The smart choice, for anyone who cares about preserving value, was and remains natural diamonds of certified quality and documented origin.
For laboratory diamonds, buy what you find beautiful. Wear it without apology. But hold no expectations about what it will be worth when circumstances change.
[ QUICK POLL // 60 SECONDS ]